Insmed Incorporated (Nasdaq:INSM) today reported financial results for the three and six months ended June 30, 2014.
Highlights of the second quarter of 2014 and recent weeks include:
•Announced plans to file a Market Authorization Application (MAA) with the European Medicines Agency (EMA) for ARIKAYCE™, or liposomal amikacin for inhalation, for the treatment of two orphan lung diseases: nontuberculous mycobacterial (NTM) lung infections in treatment refractory patients and Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF);
Help employers find you! Check out all the jobs and post your resume.
